| Title: |
Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24 separator commenting unavailable |
| Authors: |
Savulescu, Camelia; Prats Uribe, Albert; Brolin, Kim; Uusküla, Anneli; Bergin, Colm; Fleming, Catherine; Murri, Rita; Zvirbulis, Viesturs; Zavadska, Dace; Gaio, Vania; Popescu, Corneliu P.; Hrisca, Raluca; Cisneros, Maria; Latorre-Millán, Miriam; Lohur, Liis; McGrath, Jonathan; Ferguson, Lauren; De Gaetano Donati, Katleen; Abolina, Ilze; Gravele, Dagne; Machado, Ausenda; Florescu, Simin-Aysel; Lazar, Mihaela; Subirats, Pilar; Clusa, Laura; Sui, Jacklyn; Kenny, Claire; Santangelo, Rosaria; Krievins, Dainis; Barzdina, Elza Anna; Valadas Henriques, Camila; Kosa, Alma Gabriela; Pohrib, Saftica-Mariana; Muñoz-Almagro, Carmen; Milagro Beamonte , Ana; Bacci, Sabrina; Nardone, Anthony; VEBIS HCW VE study group |
| Publisher Information: |
European Centre for Disease Prevention and Control |
| Publication Year: |
2024 |
| Collection: |
UIC Open Access Archive (Universitat Internacional de Catalunya) |
| Subject Terms: |
COVID-19; Vacunació; Vacunación; Vaccination |
| Time: |
61 |
| Description: |
COVID-19 vaccination recommendations prioritise healthcare workers (HCWs), considering their exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) and their key role in the functioning of healthcare systems. In the European Union/European Economic Area (EU/EEA), HCWs were considered a priority for COVID-19 revaccination during the autumn 2023 campaign [1], and the World Health Organization (WHO) recommended revaccination of HCWs 12 months after their last dose [2]. Because the Omicron sub-lineage XBB.1.5 predominated in spring 2023, the COVID-19 vaccines were adapted to target this emerging strain, and the first XBB.1.5 vaccine was authorised for use in the EU/EEA in August 2023. Omicron BA.2.86/JN.1 emerged in the EU/EEA at the end of 2023, according to data available on the European Respiratory Virus Surveillance Summary (ERVISS) [3]. Evidence for COVID-19 vaccine recommendation in the HCW population remains scarce. Within the Vaccine Effectiveness, Burden and Impact (VEBIS) project, we aimed to measure the COVID-19 vaccine effectiveness (CVE) in HCWs, in the winter season 2023/24. ; info:eu-repo/semantics/publishedVersion |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
Eurosurveillance; 29;44; http://hdl.handle.net/20.500.12328/4484 |
| DOI: |
10.2807/1560-7917.ES.2024.29.44.2400680 |
| Availability: |
https://hdl.handle.net/20.500.12328/4484; https://doi.org/10.2807/1560-7917.ES.2024.29.44.2400680 |
| Rights: |
This work is licensed under a Creative Commons Attribution 4.0 International License. ; https://creativecommons.org/licenses/by/4.0/ ; This study was funded by European Centre for Disease Prevention and Control through “Vaccine Effectiveness, Burden and Impact Studies” (VEBIS) Lot 2 “Assessment of COVID-19 and influenza vaccine effectiveness among healthcare workers” framework contract ECDC/2021/017. ; info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.7D1B87DA |
| Database: |
BASE |